UY27692A1 - Terapias de combinación para tratar células deficientes en metiltioadenosina-fosforilasa. - Google Patents

Terapias de combinación para tratar células deficientes en metiltioadenosina-fosforilasa.

Info

Publication number
UY27692A1
UY27692A1 UY27692A UY27692A UY27692A1 UY 27692 A1 UY27692 A1 UY 27692A1 UY 27692 A UY27692 A UY 27692A UY 27692 A UY27692 A UY 27692A UY 27692 A1 UY27692 A1 UY 27692A1
Authority
UY
Uruguay
Prior art keywords
combination therapies
deficient cells
mtap
methyltioadenosine
phosphorilase
Prior art date
Application number
UY27692A
Other languages
English (en)
Inventor
Laura A Bloom
Theodore J Boritzki
Pei-Pei Kung
Richard C Ogden
Donald J Skalitzky
Luke R Zehnder
Leslie A Kuhn
Jerry J Meng
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY27692A1 publication Critical patent/UY27692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se refiere a terapias de combinación para tratar trastornos de proliferación celular asociados con células deficientes en metíltioadenosinafosforilasa ("MTAP") en un animal mamífero. Las terapias de combinación destruyen selectivamente las células MTAP- deficientes por administración de un inhibidor de la síntesis de inosinato de novo y administrando un agente anti-tóxico,en donde los inhibidores de la síntesis de inosinato de novo son inhibidores de glicinamidaribonucleótido-formiltransferasa (GARFT) y/o aminoinidazolcarboximidaribonuleótido-formiltransferasa "( AICARFT"), y el agente anti-tóxico es un análogo de un precursor de MTA o un profármaco de un sustrato de MTAP.
UY27692A 2002-03-04 2003-02-28 Terapias de combinación para tratar células deficientes en metiltioadenosina-fosforilasa. UY27692A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36164502P 2002-03-04 2002-03-04
US43227502P 2002-12-09 2002-12-09

Publications (1)

Publication Number Publication Date
UY27692A1 true UY27692A1 (es) 2003-10-31

Family

ID=27791683

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27692A UY27692A1 (es) 2002-03-04 2003-02-28 Terapias de combinación para tratar células deficientes en metiltioadenosina-fosforilasa.

Country Status (14)

Country Link
US (1) US20040043959A1 (es)
EP (1) EP1482977A1 (es)
KR (1) KR20040091089A (es)
AR (1) AR038863A1 (es)
AU (1) AU2003206019A1 (es)
BR (1) BR0308222A (es)
CA (1) CA2477422A1 (es)
IL (1) IL163776A0 (es)
NO (1) NO20044191L (es)
PA (1) PA8568201A1 (es)
PE (1) PE20030907A1 (es)
TW (1) TW200304380A (es)
UY (1) UY27692A1 (es)
WO (1) WO2003074083A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
JP2005292087A (ja) * 2004-04-05 2005-10-20 Shionogi & Co Ltd ５’−デオキシ−５’−メチルチオアデノシンに対する抗体
US7981902B2 (en) * 2006-06-28 2011-07-19 Duquesne University Of The Holy Ghost Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP5789252B2 (ja) * 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US9725479B2 (en) * 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
AU2011336415B2 (en) 2010-12-03 2016-08-11 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JPWO2016056606A1 (ja) * 2014-10-07 2017-07-20 国立大学法人京都大学 ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EA201892031A1 (ru) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5
CN108884108B (zh) * 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7054681B2 (ja) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド 組合せ療法
MX2019002962A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll.
BR112019004764A2 (pt) 2016-09-14 2019-05-28 Janssen Pharmaceutica Nv inibidores bicíclicos fundidos da interação menina-mll
MX2019003843A (es) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
EP3555103B1 (en) 2016-12-15 2021-09-22 Janssen Pharmaceutica NV Azepane inhibitors of menin-mll interaction
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN109111445B (zh) * 2018-11-02 2020-12-18 哈尔滨商业大学 5’-呋喃甲酰酯-3’-脱氧腺苷的合成方法及应用
CN109369758B (zh) * 2018-11-02 2021-04-13 哈尔滨商业大学 5′-(6-氯烟酰酯)-3′-脱氧腺苷的合成方法及其应用
EP3939988A4 (en) * 2019-03-20 2022-08-24 Korea Research Institute of Chemical Technology PHARMACEUTICAL COMPOSITION WITH NOVEL HETEROCYCLIC AZOLOPYRIMIDINE COMPOUND AS THE ACTIVE SUBSTANCE
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
WO2020249663A1 (en) 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
WO2021254529A1 (zh) * 2020-07-14 2021-12-23 江苏先声药业有限公司 双环类化合物
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori
EP4326273A1 (en) * 2021-04-19 2024-02-28 Emory University Quinazoline derivatives, pharmaceutical compositions, and therapeutic uses related to nox inhibition
CN113603721B (zh) * 2021-06-21 2023-12-01 重庆文理学院 一种合成saicar的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
US5945427A (en) * 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
JPH08504765A (ja) * 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換５−チアピリミジノンおよび５−セレノピリミジノン化合物
DK0681584T3 (da) * 1993-01-29 2001-08-27 Agouron Pharma Kondenserede, heterocykliske glutaminsyrederivater som antiproliferative midler
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5840505A (en) * 1993-12-29 1998-11-24 The Regents Of The University Of California Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells
US5942393A (en) * 1993-12-29 1999-08-24 The Regents Of The University Of California Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample
JP3473956B2 (ja) * 1994-07-28 2003-12-08 アグーロン ファーマシューティカルズ，インコーポレーテッド 抗増殖剤およびｇａｒｆｔ阻害剤として有用な化合物
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors

Also Published As

Publication number Publication date
US20040043959A1 (en) 2004-03-04
NO20044191L (no) 2004-09-30
CA2477422A1 (en) 2003-09-12
WO2003074083A1 (en) 2003-09-12
EP1482977A1 (en) 2004-12-08
AR038863A1 (es) 2005-02-02
KR20040091089A (ko) 2004-10-27
BR0308222A (pt) 2005-02-09
IL163776A0 (en) 2005-12-18
AU2003206019A1 (en) 2003-09-16
PA8568201A1 (es) 2003-11-12
PE20030907A1 (es) 2003-10-29
TW200304380A (en) 2003-10-01

Similar Documents

Publication Publication Date Title
UY27692A1 (es) Terapias de combinación para tratar células deficientes en metiltioadenosina-fosforilasa.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
DE602006020335D1 (de) Verwendung von parp-1-hemmern
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0109161A (pt) Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
GT200000107A (es) Procedimiento para la obtencion de "compuestos de indazol y composiciones farmaceuticas para inhibir las quinasas deproteina y metodos para su uso".
TW200720250A (en) Benzene, pyridine, and pyridazine derivatives
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
NO20050198D0 (no) Mitotiske kinesininhibitorer
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
AR056586A1 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126